Clinical Trial Update: SELINE: Second-Line Iressa Phase IV Study in NSCLC Patients [Phase 4]

View source ↗

Summary

This document reports results from the Phase IV SELINE trial evaluating Iressa (gefitinib) as second-line therapy in non-small cell lung cancer. The trial is co…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Iressa (gefitinib)

Snippet

Sponsor: AstraZeneca | Conditions: Non Small Cell Lung Carcinoma | Phase 4 | Status: COMPLETED | Results posted: 2012-09-28